ストックスクリーナーアプリを入手
2.24
3.03%
-0.07
前日終値:
$2.31
開ける：
$2.29
24時間の取引高:
369.00K
Relative Volume:
0.16
時価総額：
$239.72M
収益：
$27.08M
当期純損益:
$-37.00M
株価収益率:
-4.3077
EPS:
-0.52
ネットキャッシュフロー:
$-18.46M
1週間 パフォーマンス:
-3.86%
1か月 パフォーマンス:
-13.85%
6か月 パフォーマンス:
+76.38%
1年 パフォーマンス:
+86.67%
1日の値動き範囲:
$2.22
$2.335
1週間の範囲:
$2.22
$2.415
52週間の値動き範囲:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
ACRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.24 | 239.72M | 27.08M | -37.00M | -18.46M | -0.52 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-11-19 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 開始されました | Evercore ISI | Outperform |
| 2022-12-14 | 開始されました | Stifel | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-10-06 | 開始されました | BTIG Research | Buy |
| 2021-07-23 | 再開されました | Jefferies | Buy |
| 2021-06-15 | 開始されました | Piper Sandler | Overweight |
| 2021-04-21 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 開始されました | SVB Leerink | Outperform |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2018-02-09 | 開始されました | Guggenheim | Buy |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 開始されました | Leerink Partners | Outperform |
| 2016-09-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-06-10 | 開始されました | Guggenheim | Buy |
| 2015-11-02 | 開始されました | Citigroup | Buy |
| 2015-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Aclaris Therapeutics Inc (ACRS) 最新ニュース
Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday - MarketBeat
Common Warts Market to Expand Significantly by 2034, States - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January - MarketBeat
Peapod Lane Capital LLC Takes $1 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewswire
Clinical Data: Revolutionary Dual-Target Drug Shows Promise for Multiple Autoimmune Conditions - StockTitan
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Financial Metrics Check: Aclaris Therapeutics Inc (ACRS)’s Ratios for Trailing Twelve Months - The Dwinnex
Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha
What is Leerink Partnrs' Forecast for ACRS FY2029 Earnings? - MarketBeat
H.C. Wainwright gives a Buy recommendation for Aclaris Therapeutics Inc (ACRS) - Knox Daily
Leerink Partnrs Has Negative Outlook of ACRS FY2025 Earnings - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2029 Earnings - Armenian Reporter
StockNews.com Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Sell - Defense World
Aclaris Therapeutics Inc (ACRS) Shares Decline Despite Market Challenges - The News Heater
Aclaris Therapeutics Inc (ACRS) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
What is Leerink Partnrs’ Forecast for ACRS FY2025 Earnings? - Armenian Reporter
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Analysts - MarketBeat
Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $2.98 - Knox Daily
Aclaris Therapeutics forms new Scientific Advisory Board - MSN
The Aclaris Therapeutics Inc (ACRS) had a good session last reading, didn’t it? - US Post News
Aclaris Therapeutics Inc (ACRS)’s Market Momentum: Closing Strong at 2.40, Down -3.23 - The Dwinnex
Healthy Upside Potential: Aclaris Therapeutics Inc (ACRS) - SETE News
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Cut to Sell at StockNews.com - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Cantor Fitzgerald - Defense World
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in January - Defense World
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewswire
Aclaris Therapeutics forms new Scientific Advisory Board By Investing.com - Investing.com Canada
Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz
Assenagon Asset Management S.A. Acquires 211,585 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Cantor Fitzgerald Comments on ACRS FY2025 Earnings - Defense World
Aclaris Therapeutics Inc (ACRS) 財務データ
収益
当期純利益
現金流量
EPS
Aclaris Therapeutics Inc (ACRS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
0.06%
3.50%
大文字化:
|
ボリューム (24 時間):